Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6090521 | 0.85 | ALDH1A1 (0.37) | ALDH1A1DRD4TSHRMEN1LMNA | |
| SCHEMBL6091299 | 0.82 | LMNA (0.38) | ALDH1A1MAPTDRD4TSHRLMNA | |
| SCHEMBL16366465 | 0.81 | KDM4E (0.41) | ALDH1A1DRD4MEN1KMT2A | |
| SCHEMBL6091583 | 0.77 | KDM4E (0.42) | ALDH1A1DRD4TSHRMEN1KMT2A | |
| SCHEMBL6092971 | 0.75 | KDM4E (0.42) | ALDH1A1MAPTDRD4TSHRMEN1 | |
| SCHEMBL6091289 | 0.75 | KDM4E (0.42) | ALDH1A1MAPTDRD4TSHRMEN1 | |
| SCHEMBL6089125 | 0.75 | KDM4E (0.42) | ALDH1A1MAPTDRD4TSHRMEN1 | |
| SCHEMBL6089444 | 0.75 | KDM4E (0.42) | ALDH1A1MAPTDRD4TSHRMEN1 | |
| Hydrochloric Acid SCHEMBL6091722 | 0.74 | KDM4E (0.41) | ALDH1A1MAPTDRD4TSHRMEN1 | |
| SCHEMBL6091122 | 0.73 | KDM4E (0.41) | ALDH1A1MAPTDRD4TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | PARP1, PARP2, PARP11 | ALDH1A1 1890/4885MAPT 497/4885ALOX15 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.